Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Metformin Stories

2012-03-23 09:39:06

Programs to prevent or delay type 2 diabetes in high-risk adults would result in fewer people developing diabetes and lower health care costs over time, researchers conclude in a new study funded by the National Institutes of Health. Prevention programs that apply interventions tested in the landmark Diabetes Prevention Program (DPP) clinical trial would also improve quality of life for people who would otherwise develop type 2 diabetes. The analysis of costs and outcomes in the DPP and...

2012-03-08 10:39:48

Metformin treatment seen to prevent growth of calcium deposits in coronary arteries Treatment with the common diabetes drug metformin appears to prevent progression of coronary atherosclerosis in patients infected with HIV. In a presentation today at the 19th Conference on Retroviruses and Opportunistic Infections, Massachusetts General Hospital (MGH) researchers reported that study participants receiving daily doses of metformin had essentially no progression of coronary artery...

2012-03-07 07:00:00

RIDGEFIELD, Conn. and INDIANAPOLIS, March 7, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced Jentadueto(TM) (linagliptin/metformin hydrochloride) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S. JENTADUETO is a new prescription medication for patients who need to control their blood sugar. Taken twice daily, it combines two diabetes medicines - the dipeptidyl...

2012-02-26 17:36:00

DEERFIELD, Ill. and OSAKA, Japan, Feb. 26, 2012 /PRNewswire/ -- Phase 2 clinical data of an investigational type 2 diabetes therapy, TAK-875 of Takeda Pharmaceutical Company Limited ("Takeda"), were published online first in The Lancet. The clinical trial was conducted by Takeda's wholly owned subsidiary, Takeda Global Research & Development Center, Inc. in Deerfield, Illinois. These data, which were presented at the American Diabetes Association 71st Annual Scientific Sessions,...

2012-02-07 10:09:49

ACP issues new clinical practice guideline for drug treatment of type 2 diabetes The American College of Physicians (ACP) recommends that clinicians add metformin as the initial drug treatment for most patients with type 2 diabetes when lifestyle modifications such as diet, exercise, and weight loss have failed to adequately improve high blood sugar. ACP also recommends that clinicians add a second drug to metformin when treatment with metformin and lifestyle changes fail to control...

2012-01-30 17:50:00

RIDGEFIELD, Conn., and INDIANAPOLIS, Jan. 30, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto(TM) (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin. JENTADUETO provides a new, single-tablet treatment option, taken twice-daily, for patients who need to control...

2012-01-09 15:30:00

THE WOODLANDS, Texas, Jan. 9, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today top-line results from the first clinical study testing the combined effects of LX4211, a novel sodium glucose transporter 1 and 2 (SGLT1 and SGLT2) inhibitor, with the dipeptidyl peptidase 4 (DPP-4) inhibitor, sitagliptin (Januvia®), one of the most widely prescribed diabetes drugs. "The results of this study are important given that combination...

2012-01-09 06:30:00

PITTSBURGH, Jan. 9, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that the company has been sued by Takeda Pharmaceutical Company, Watson Pharmaceuticals and Andrx Labs in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Pioglitazone Hydrochloride and Extended-release Metformin Hydrochloride tablets, 15 mg/1000 mg and 30 mg/1000 mg. This product is the generic version of Actoplus Met® XR,...

2012-01-06 14:45:41

Drug manufacturer deviates from appropriate comparator therapy specified by the G-BA Linagliptin (trade name: Trajenta®) has been approved since August 2011 to improve blood glucose control ("glycaemic control") in adults with type 2 diabetes mellitus whose elevated blood glucose levels are inadequately controlled by diet and exercise. It is an option for patients who do not tolerate or should not take the usual treatment with the drug metformin. Moreover, linagliptin can be added if...

2011-12-08 07:00:00

MOUNTAIN VIEW, Calif., Dec. 8, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that results from the SEQUEL study were published in The American Journal of Clinical Nutrition, a peer-reviewed journal with broad, multidisciplinary readership. The SEQUEL study evaluated the long-term efficacy and safety of Qnexa in 676 overweight and obese subjects with cardiometabolic disease. In addition to 10% sustained weight loss, the study also found that significantly more...